Trials / Terminated
TerminatedNCT03892525
Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma
Phase Ib Study Evaluating the Safety and Efficacy of Intratumoral Agonistic Anti-CD40 (Selicrelumab) in Combination With Anti-PDL1 (Atezolizumab) in Patients With Refractory or Relapsed B Cell Lymphoma
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- The Lymphoma Academic Research Organisation · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open, dose escalation phase Ib trial of intratumoral agonistic anti-CD40 Ab (Selicrelumab intratumoral every 3 weeks for 3 cycles) in combination with anti-PDL1 Ab (Atezolizumab 1200mg intravenous every 3 weeks) in patients with refractory or relapsed B cell lymphoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Selicrelumab | escalated dose in intratumoral injection, every 3 weeks, for 3 cycles |
| DRUG | Atezolizumab | 1200mg IV every 3 week until progression or relapse for maximum 1 year |
Timeline
- Start date
- 2019-07-04
- Primary completion
- 2021-04-07
- Completion
- 2021-04-07
- First posted
- 2019-03-27
- Last updated
- 2021-07-26
Locations
5 sites across 1 country: France
Source: ClinicalTrials.gov record NCT03892525. Inclusion in this directory is not an endorsement.